‘Hepatitis patient dropouts pose infection threat’ - Hindustan Times
close_game
close_game

‘Hepatitis patient dropouts pose infection threat’

By, Lucknow
Nov 25, 2023 05:46 AM IST

Dropout among hepatitis patients in India is a risk, as it may lead to the spread of infection to high-risk groups. A study found that a large percentage of hepatitis B and C infections remain undiagnosed. Regular feedback and tracking are needed to minimize dropout rates.

Dropout among identified hepatitis patients poses a threat, as they may spread infection to others in high-risk behaviour groups, such as sex workers and injectable drug users, said Dr Archana Pawar, a Mumbai-based microbiologist while addressing MICROCON-2023, a five-day national conference of the Indian Association of Medical Microbiologists at King George’s Medical University (KGMU).

For representation only (HT Photo)
For representation only (HT Photo)

Presenting a study conducted with over 26,000 patients between January and June 2023, Dr Pawar said, “It is estimated that 90% of the hepatitis B and 79% of hepatitis C infections remain undiagnosed.” Dr Pawar works at Lokmanya Tilak Municipal Medical College and General Hospital, Mumbai.

Hindustan Times - your fastest source for breaking news! Read now.

“India falls in the intermediate endemicity group with hepatitis B prevalence rate of 0.87% to 21.4% hepatitis C prevalence rate between 0.19% and 53.7%. This signifies any dropout among identified hepatitis patient is a risk,” she said.

She further shared among hepatitis B patients we identified only 20.84% enrolled at model treatment centre and among hepatitis C 31.02% enrolled.

“To check drop out regular feedback and tracking is needed. This if applied with every identified/enrolled patient will bring down dropout rate to minimum,” said Dr Sumit Rungta, head of gastroenterology department at KGMU.

SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Sunday, March 03, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On